Concepedia

Doug Fecteau

DF

3

Publications

107

Citations

3

H-Index

2013

Active since

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

GlaxoSmithKline (United Kingdom)

Doug Fecteau is an author at Research Triangle Park Foundation specializing in oncology, cancer research, and cancer therapeutics.

Top concepts

Publications per year

2013–2019

3

Publications

3

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Matthew J. Matasar, Myron S. Czuczman, Maria Alma Rodriguez et al. · Blood · 2013 · 64 citations · Full text

Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Katja Weisel, Thomas G. Hopkins, Doug Fecteau et al. · Blood · 2019 · 29 citations

DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Suzanne Trudel, Ajay K. Nooka, Doug Fecteau et al. · Annals of Oncology · 2019 · 14 citations · Full text

, , +9

Rows per page

1–3 of 3